Investors need to pay close attention to About Alkermes (ALKS) stock based on the movements in the options market lately.

Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model.

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar ...

CHICAGO: CG Life has acquired New York City-based Berry & Company Public Relations. The deal, which closed on May 6, expands ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) yesterday ...

The Kiwanis Club of Wilmington held its annual Bike Rodeo on Saturday starting at the parking lot of Clinton Memorial ...

A new study tested a well-known smoking cessation drug to see if it would work to help people to quit e-cigarettes.

The price-to-earnings ratio for Alkermes plc (NASDAQ:ALKS) is 9.65. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E ...

Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan. Check the time stamp on this data. Updated AI-Generated Signals for Alkermes Plc (ALKS) ...

Community input varied. Representatives from Alkermes and EMSAR expressed strong support, emphasizing how their employees would benefit from the trail. Conversely, a resident raised concerns about the ...

Market OverviewThe Addiction Rehab Facilities Market, valued at USD 16.8 billion in 2023, is anticipated to experience substantial growth, reaching about USD 31.3 billion by 2032. This growth ...